

Belotero® Intense


A close-up portrait of a woman with dark hair and brown eyes, resting her chin on her hand. A circular graphic with two arrows forming a loop is overlaid on her cheek.

OPTIMAL
TISSUE
SUPPORT

INTENSE

Belotero® Intense* offers effective filling capacity and natural looking results due to balanced elasticity

Finding the right elasticity to suit your patients' needs and expectations is a matter of balance in order to provide optimal skin support.




Belotero® Intense provides optimal filling capacity for predictable, natural looking results whilst maintaining excellent tissue integration to minimise lumps and bumps.

* Belotero® Intense is equivalent to Fortélis® Extra, a registered trademark by Anteis S.A.


BELOTERO® INTENSE

Efficacy was demonstrated in a study of 149 patients to assess the efficacy and safety of Belotero® Intense²⁵

Mean WSRS improved significantly by 1.9 score points without any decline throughout the 12-week period.



89.9% of patients achieved improvement on the Investigator assessed Global Aesthetic Improvement Scale immediately after injection. The aesthetic effect was well maintained throughout the 3-month evaluation period.



Adverse events were localised to the injection area and occurred in 85.9% of patients immediately after injection and declined to 12.8% in week 2. None were serious.

²⁵ Pavicic T. Efficacy and Tolerability of a New Monophasic, Double-Crosslinked Hyaluronic Acid Filler for Correction of Deep Lines and Wrinkles. Journal of Drugs in Dermatology. 2011. 10(2); 134-139.

BELOTERO® INTENSE

Belotero® Intense provides lasting results and high patient satisfaction without producing lumps²⁶

A double-blind, half-side comparison study of 20 patients with symmetric nasolabial folds who were randomised to contralateral treatment with Belotero® Intense and a biphasic HA filler (NASHA). Efficacy was assessed at baseline and after 2, 24, and 48 weeks using a wrinkle severity rating scale, subject questionnaire, and biophysical in vivo methods.


Lasting results

All subjects showed significant improvements with both fillers up to day 365.

Patient satisfaction

At week 24, improvement of patient satisfaction was significantly greater with Belotero® Intense, $p < 0.001$; NASHA, $p = 0.006$).

24 and 48 weeks after initial injection, significantly more subjects treated with Belotero® Intense judged themselves as satisfied compared with NASHA (24 weeks: $p = 0.002$; 48 weeks: $p = 0.005$).



After 48 weeks patient satisfaction with Belotero® Intense was significantly greater than at baseline but satisfaction on the NASHA had returned to baseline value.

Subject questionnaire confirmed that 80% of subjects treated with Belotero® Intense and 65% of subjects injected with NASHA filler stated that their expectations were met and that they would repeat the treatment course.

“These results may be due to the unique structure of Belotero® Intense which allows it to spread more regularly and fill the dermal volume defect more evenly than the biphasic product.”

²⁶ Buntrock H, Reuther T, Prager W, Kerscher M. Efficacy, safety, and patient satisfaction of a monophasic cohesive polydensified matrix versus a biphasic nonanimal stabilized hyaluronic acid filler after single injection in nasolabial folds. *Dermatol Surg.* 2013; 39(7):1097-105.

Minimal risk of local inflammatory reaction with Belotero® Intense compared to others²⁷


A study to assess the safety criteria of aesthetic filler materials by investigating intradermal reactions after implantation of 0.2 ml dermal filler in mapped abdominal skin areas showed no abnormality and no significant local inflammatory reaction after Belotero® injection.

Histological slides 30 days after injection

Lymphocytes (L)
Plasma cells (P)
Eosinophil granulocytes (EG)




- No histomorphological inflammation reaction
- Even distribution of injection material



- Light to moderate chronic inflammation
- Increased lymphocytes, plasma cells, and eosinophil granulocytes
- Irregular distribution of injection material



- Intense chronic inflammation
- Heavy infiltration of lymphocytes, plasma cells, and eosinophil granulocytes
- Irregular distribution of injection material



- Intense chronic inflammation
- Irregular infiltration of lymphocytes and plasma cells

²⁷ Taufig A, et al., A new strategy to detect intradermal reactions after injection of resorbable dermal fillers. J Ästhetische Chirurgie 2009; 2: 29-36.

Predictable results with Belotero® Intense*

Lip augmentation



Before



After

Face contours, nasolabial folds and lip enhancement



Before



After

Nasolabial folds and lip enhancement



Before








After

* Courtesy of Dr Micheels



The Belotero® family – It's a part of you



Belotero® product	Indications	HA concentration	Needle size	Injection site and angle
HYDRO	Skin rehydration, e.g.: face, neck, décolletage, back of hands	18 mg/1ml	30 G	Dermal/epidermal junction (nappage technique) or superficial dermis (micro-papular technique) 
SOFT	Correction of fine lines, e.g.: crow's feet, perioral lines, fine forehead lines	20 mg/1ml	30 G	Superficial dermis Approx 10° 
BALANCE	Correction of moderate lines, e.g.: moderate nasolabial wrinkle, glabellar lines, moderate perioral wrinkles, lip contouring, philtrum	22.5 mg/1ml	27 G	Superficial to mid dermis Approx 15° 
INTENSE	Correction of deeper lines, e.g.: severe nasolabial fold, lip volume, oral commissures, marionette folds	25.5 mg/1ml	27 G	Mid and deep dermis Approx 30° 
VOLUME	Restoration of facial volumes, e.g.: cheeks, temples, facial volume loss	26 mg/1ml	30 G + 27 G Needle Cannula	Deep dermis, subcutaneously 

MERZ AESTHETICS



Belotero® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100
60318 Frankfurt am Main, Germany
www.merzaesthetics.com

Belotero® is manufactured by Anteis S.A.
18, Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland

